Purpose: To compare effectiveness and safety of the gel stent to trabeculectomy in open-angle glaucoma (OAG).

Design: Prospective, randomized, multicenter, noninferiority study.

Methods: Patients with OAG and intraocular pressure (IOP) 15 to 44 mm Hg on topical IOP-lowering medication were randomized 2:1 to gel stent implantation or trabeculectomy. Primary end point (surgical success): percentage of patients at month 12 achieving ≥20% IOP reduction from baseline without medication increase, clinical hypotony, vision loss to counting fingers, or secondary surgical intervention (SSI) in a noninferiority test with 24% margins. Secondary end points (month 12) included mean IOP and medication count, postoperative intervention rate, visual recovery, and patient-reported outcomes (PROs). Safety end points included adverse events (AEs).

Results: At month 12, the gel stent was statistically noninferior to trabeculectomy (between-treatment difference [Δ], -6.1%; 95% CI, -22.9%, 10.8%); 62.1% and 68.2% achieved the primary end point, respectively (P=.487); mean IOP and medication count reductions from baseline were significant (P<.001); and the IOP change-related Δ (2.8 mm Hg) favored trabeculectomy (P=.024). The gel stent resulted in fewer eyes requiring in-office postoperative interventions (P=.024 after excluding laser suture lysis), faster visual recovery (P≤.048), and greater 6-month improvements in visual function problems (ie, PROs; P≤.022). The most common AEs were reduced visual acuity at any time (gel stent, 38.9%; trabeculectomy, 54.5%) and hypotony (IOP <6 mm Hg at any time) (gel stent, 23.2%; trabeculectomy, 50.0%).

Conclusions: At month 12, the gel stent was statistically noninferior to trabeculectomy, per the percentage of patients achieving ≥20% IOP reduction from baseline without medication increase, clinical hypotony, vision loss to counting fingers, or SSI. Trabeculectomy achieved a statistically lower mean IOP, numerically lower failure rate, and numerically lower need for supplemental medications. The gel stent resulted in fewer postoperative interventions, better visual recovery, and fewer AEs.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ajo.2023.03.026DOI Listing

Publication Analysis

Top Keywords

gel stent
16
randomized multicenter
8
effectiveness safety
8
primary point
8
iop medication
8
medication count
8
gel
4
stent versus
4
trabeculectomy
4
versus trabeculectomy
4

Similar Publications

Aim: To evaluate the short-term efficacy of XEN45 Gel Stent (XEN) implantation for primary open angle glaucoma (POAG) and pseudoexfoliation (PEX) glaucoma across two university eye clinics, aiming to assess the impact of varying center-specific protocols during the first postoperative year.

Methods: We retrospectively examined 282 patients (183 in center 1, 99 in center 2), who underwent XEN microstent implantation for uncontrolled POAG or PEX glaucoma. Parameters including intraocular pressure (IOP), IOP-lowering medication count, best corrected visual acuity (BCVA), and postoperative complications were evaluated over 12mo.

View Article and Find Full Text PDF

This video demonstrates the novel "macaroni necklace" technique for removing a Xen gel stent. The technique allows for complete removal of the stent without the hydrated and soft pieces from tearing apart. In this case, the stent was the nidus for endophthalmitis, and complete removal is necessary for prevention of future infections.

View Article and Find Full Text PDF
Article Synopsis
  • The study compared clinical outcomes of Xen 45 gel stent surgery and trabeculectomy in glaucoma patients, analyzing data from 62 eyes treated with Xen and 78 eyes with trabeculectomy over specific periods.
  • Results showed a lower complete success rate for Xen (33.9%) compared to trabeculectomy (57.7%), along with higher postoperative intraocular pressure and more glaucoma medications needed in the Xen group; however, it had fewer complications (0% vs. 16.7%) and shorter operation time.
  • Both surgical methods yielded similar postoperative best corrected visual acuity but differed in success rates, medication requirements, and safety profiles, indicating that while Xen may be quicker and safer
View Article and Find Full Text PDF

Research Progress on the Application of Natural Medicines in Biomaterial Coatings.

Materials (Basel)

November 2024

School of Materials Science and Engineering, Zhengzhou University, Zhengzhou 450001, China.

With the continuous progress of biomedical technology, biomaterial coatings play an important role in improving the performance of medical devices and promoting tissue repair and regeneration. The application of natural medicine to biological materials has become a hot topic due to its diverse biological activity, low toxicity, and wide range of sources. This article introduces the definition and classification of natural medicines, lists some common natural medicines, such as curcumin, allicin, chitosan, tea polyphenols, etc.

View Article and Find Full Text PDF
Article Synopsis
  • This study aimed to assess the effectiveness and safety of a new surgical method called transconjunctival XEN® 45 gel stent implantation in treating primary open-angle glaucoma (POAG).
  • A total of 31 patients underwent the procedure, experiencing an average decrease in intraocular pressure from 25.3 mm Hg pre-surgery to 15.9 mm Hg post-surgery, with most not needing additional medications by the one-month follow-up.
  • The results suggest that this surgical technique is both safe and effective, offering a timely alternative for patients with POAG needing surgical intervention earlier in their treatment process.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!